New cocktail aims to deeply shrink myeloma in early treatment
NCT ID NCT04113018
First seen Feb 03, 2026 · Last updated May 20, 2026 · Updated 15 times
Summary
This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in 39 adults newly diagnosed with multiple myeloma, a blood cancer. The goal is to see how many patients achieve a complete or very deep response after initial treatment. While multiple myeloma is not considered curable, this approach aims to control the disease more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
Conditions
Explore the condition pages connected to this study.